NEWS
The king returns! Leading vaccine company Aimei Vaccine launches return to A-shares, with multiple heavyweight products set to be listed soon
This year's Nobel Prize once again dominated the hot topics list with the previously renowned mRNA technology. The good news is that the leading vaccine company Aimei Vaccine (06660.HK), which carries the heavyweight weapon mRNA technology platform and possesses five major technological platforms including bacterial vaccines and genetic engineering vaccines, has recently announced that the company has decided to initiate an A-share listing plan, which has been approved by the board of directors.
With Aimei Vaccine's return to A-shares, some institutions have seen the distinct advantages of A+H layout. A-shares have a significant valuation premium compared to H-shares, and the market value of the company's H-shares will also rise accordingly.
According to data as of September 28th this year, medical companies listed in both Shanghai and Hong Kong, such as Fudan Zhangjiang A/H shares, have a valuation premium of 3.9 times, Xinhua Pharmaceutical has a premium of 3.6 times, and Junshi Biology has a premium of 2.1 times. Overall, A-share market values can obtain an average valuation premium of 2.5 times compared to H-share listings. Similarly, for vaccine companies like Consino, A/H shares have a valuation premium of 3.1 times.
The splendid prospects of the vaccine race have long been demonstrated by data. According to reports from Insight Consulting, the global vaccine market is expected to grow from $64 billion in 2021 to $112.7 billion by 2030 (excluding COVID-19 vaccines), indicating tremendous market growth potential.
On this evergreen track, the big player Aimei Vaccine has unique advantages. Industry insiders analyze that among all vaccine companies in China, Aimei Vaccine is the only one that simultaneously has seven research and development teams, seven pilot plants, and is concurrently advancing five Phase III clinical projects.
Aimei Vaccine not only has eight marketed vaccine products but also holds long-term leading market shares in hepatitis B and rabies vaccines. Its 23 in-development vaccines cover 14 disease areas, with five of the 14 products having obtained clinical approvals entering Phase III trials. The mid-term performance release shows strong certainty. According to the company's 2023 interim report, the "king of vaccines," including the 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, and serum-free human rabies vaccine, are all in the final stages or sprinting phases of Phase III clinical trials with rapid progress towards market entry. The market size of the pneumonia vaccine alone exceeds 50 billion yuan.
In the hot field of mRNA technology, according to the company's semi-annual report, Aimei Vaccine has a total of eight clinical approvals internationally and domestically. Its in-development mRNA rabies vaccine is China's first non-COVID mRNA vaccine accepted for review. The in-development mRNA herpes zoster vaccine is a world-class innovative product targeting the elderly market, while the mRNA respiratory syncytial virus (RSV) vaccine is another heavyweight product targeting respiratory system diseases.
The construction of Aimei Vaccine's 23-valent pneumococcal polysaccharide vaccine production workshop with a designed capacity of 15 million doses has been completed. The construction of the mRNA COVID-19 vaccine production workshop with a designed capacity of 200 million doses, the serum-free rabies vaccine with a designed capacity of 50 million doses, and the 13-valent pneumococcal conjugate vaccine workshop with a designed capacity of 30 million doses has also been completed. The pre-production preparation work for the aforementioned Phase III clinical projects is ready. Once approved for market entry, the production capacity will be rapidly unleashed.
Looking across the current Chinese vaccine companies, Aimei Vaccine demonstrates unique advantages in multiple dimensions. In terms of research and development capabilities, unlike other companies that collaborate externally, Aimei has an independent innovation mRNA technology platform, helping it seize the first-mover advantage in the next round of vaccine technology revolution. Furthermore, Aimei is the only Chinese company that possesses all five validated human vaccine technology platforms, and each technology platform has in-development products in clinical trials. In terms of industrialization, Aimei has built modern production workshops with a total capacity of 540 million doses, far exceeding that of similar enterprises.
Some industry analysts conclude that, under the triple resonance of an impending performance explosion, the imminent implementation of additional offerings, and a strong technical form, the window period during which Aimei Vaccine is worth strategic investor attention is also set to emerge.
With Aimei Vaccine's return to A-shares, some institutions have seen the distinct advantages of A+H layout. A-shares have a significant valuation premium compared to H-shares, and the market value of the company's H-shares will also rise accordingly.
According to data as of September 28th this year, medical companies listed in both Shanghai and Hong Kong, such as Fudan Zhangjiang A/H shares, have a valuation premium of 3.9 times, Xinhua Pharmaceutical has a premium of 3.6 times, and Junshi Biology has a premium of 2.1 times. Overall, A-share market values can obtain an average valuation premium of 2.5 times compared to H-share listings. Similarly, for vaccine companies like Consino, A/H shares have a valuation premium of 3.1 times.
The splendid prospects of the vaccine race have long been demonstrated by data. According to reports from Insight Consulting, the global vaccine market is expected to grow from $64 billion in 2021 to $112.7 billion by 2030 (excluding COVID-19 vaccines), indicating tremendous market growth potential.
On this evergreen track, the big player Aimei Vaccine has unique advantages. Industry insiders analyze that among all vaccine companies in China, Aimei Vaccine is the only one that simultaneously has seven research and development teams, seven pilot plants, and is concurrently advancing five Phase III clinical projects.
Aimei Vaccine not only has eight marketed vaccine products but also holds long-term leading market shares in hepatitis B and rabies vaccines. Its 23 in-development vaccines cover 14 disease areas, with five of the 14 products having obtained clinical approvals entering Phase III trials. The mid-term performance release shows strong certainty. According to the company's 2023 interim report, the "king of vaccines," including the 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, and serum-free human rabies vaccine, are all in the final stages or sprinting phases of Phase III clinical trials with rapid progress towards market entry. The market size of the pneumonia vaccine alone exceeds 50 billion yuan.
In the hot field of mRNA technology, according to the company's semi-annual report, Aimei Vaccine has a total of eight clinical approvals internationally and domestically. Its in-development mRNA rabies vaccine is China's first non-COVID mRNA vaccine accepted for review. The in-development mRNA herpes zoster vaccine is a world-class innovative product targeting the elderly market, while the mRNA respiratory syncytial virus (RSV) vaccine is another heavyweight product targeting respiratory system diseases.
The construction of Aimei Vaccine's 23-valent pneumococcal polysaccharide vaccine production workshop with a designed capacity of 15 million doses has been completed. The construction of the mRNA COVID-19 vaccine production workshop with a designed capacity of 200 million doses, the serum-free rabies vaccine with a designed capacity of 50 million doses, and the 13-valent pneumococcal conjugate vaccine workshop with a designed capacity of 30 million doses has also been completed. The pre-production preparation work for the aforementioned Phase III clinical projects is ready. Once approved for market entry, the production capacity will be rapidly unleashed.
Looking across the current Chinese vaccine companies, Aimei Vaccine demonstrates unique advantages in multiple dimensions. In terms of research and development capabilities, unlike other companies that collaborate externally, Aimei has an independent innovation mRNA technology platform, helping it seize the first-mover advantage in the next round of vaccine technology revolution. Furthermore, Aimei is the only Chinese company that possesses all five validated human vaccine technology platforms, and each technology platform has in-development products in clinical trials. In terms of industrialization, Aimei has built modern production workshops with a total capacity of 540 million doses, far exceeding that of similar enterprises.
Some industry analysts conclude that, under the triple resonance of an impending performance explosion, the imminent implementation of additional offerings, and a strong technical form, the window period during which Aimei Vaccine is worth strategic investor attention is also set to emerge.
Previous：After listing in Hong Kong for a year, Aimei vaccines initiates its A-share plan. The advisory institution is changed from CITIC Construction Investment to CITIC Securities.
Next：Aimei Vaccine's heavy single product is about to enter the harvest period, and its growth momentum is unstoppable
